News | January 27, 2022
Moderna working on Omicron-specific booster candidate
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
The company has been manufacturing masks since the Covid-19 outbreak in 2020
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The country is sixth among the most affected countries by active cases
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
It provides Covid-19 detection and Omicron surveillance in less than two hours
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Subscribe To Our Newsletter & Stay Updated
